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Background:  Puerarin  is  the most  abundant  isoﬂavonoid  in  kudzu  root.  It  has  been  used  to  treat  angina
pectoris  and  myocardial  infarction  clinically.  However,  little  is  known  about  the  effect  of  puerarin  on
cardiac  hypertrophy.
Methods: Aortic  banding  (AB)  was  performed  to  induce  cardiac  hypertrophy  in mice.  Puerarin  premixed
in  diets  was  administered  to mice  after  one  week  of AB. Echocardiography  and  catheter-based  mea-
surements  of  hemodynamic  parameters  were  performed  at 7 weeks  after  starting  puerarin  treatment  (8
weeks  post-surgery).  The  extent  of  cardiac  hypertrophy  was also  evaluated  by  pathological  and  molecu-
lar  analyses  of  heart  samples.  Cardiomyocyte  apoptosis  was  assessed  by  measuring  Bax  and  Bcl-2  protein
expression  and  terminal  deoxynucleotidyl  transferase  dUTP  nick  end  labeling  staining.  In  addition,  the
inhibitory  effect  of puerarin  (1 M,  5  M, 10 M, 20 M, 40 M)  on mRNA  expression  of  atrial  natri-
uretic  peptide  (ANP)  and  B-type  natriuretic  peptide  (BNP)  in Ang  II (1  M)-stimulated  H9c2  cells  was
investigated  using  quantitative  real-time  reverse  transcription-polymerase  chain  reaction.
Results: Echocardiography  and  catheter-based  measurements  of  hemodynamic  parameters  at  7 weeks
revealed  the  amelioration  of systolic  and  diastolic  abnormalities.  Puerarin  also  decreased  cardiac  ﬁbrosis
in  AB  mice.  Moreover,  the  beneﬁcial  effect  of puerarin  was  associated  with  the  normalization  in  gene
expression  of  hypertrophic  and  ﬁbrotic  markers.  Further  studies  showed  that  pressure  overload  signif-
icantly  induced  the  activation  of  phosphoinositide  3-kinase  (PI3K)/Akt  signaling  and  c-Jun  N-terminal
kinase  (JNK)  signaling,  which  was  blocked  by  puerarin  treatment.  Cardiomyocyte  apoptosis  and  induc-
tion  of  Bax  in  response  to AB  were  suppressed  by  puerarin.  Furthermore,  the  increased  mRNA  expression
of  ANP  and  BNP  induced  by  Ang II (1 M)  was  restrained  to  a different  extent  by  different  concentrations
of  puerarin.
Conclusion:  Puerarin  may  have  an  ability  to retard  the  progression  of cardiac  hypertrophy  and  apoptosis
which  is probably  mediated  by the  blockade  of PI3K/Akt  and JNK  signaling  pathways.
3  Jap© 201
ntroduction
Pathological cardiac hypertrophy is classically considered as a
ondition at the boundary between the normal and the progres-
ively failing heart [1]. Preventing or reducing pathological cardiac
ypertrophy is an independent therapeutic goal, and might serve
o prevent or postpone the progression of heart failure [2]. Current
harmacotherapies for heart failure have proven to be beneﬁcial
n improving the quality of life for heart failure patients without
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remarkably reducing mortality rates [3]. The high mortality rates of
heart failure may  reﬂect the complexity of hypertrophic processes
that contribute to heart failure and the difﬁculty in reversing car-
diac hypertrophy with current pharmacotherapies [4]. The future
challenge will be to ﬁnd new pharmacological agents that target
the underlying pathophysiological processes, including relevant
signaling pathways and cardiac ﬁbrosis, which lead to progres-
sive myocardial dysfunction and unfavorable remodeling, and thus
improve the long-term clinical outcomes of patients with heart
failure [5].
Puerarin (7,4′-dihydroxy-8--d-glucosylisoﬂavone, C21H20O9)
[6], the major bioactive constituent in kudzu root, is used widely
in China for the treatment of cardiovascular diseases and diabetes
[7]. In addition, previous studies suggest that puerarin possesses
anti-oxidant [8], anti-platelet [9], anti-inﬂammatory [10], anti-
arrhythmic [11], and anti-apoptotic properties [12]. It is also
vier Ltd. All rights reserved.
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eported that puerarin could promote neovascularization in the
yocardium of rats suffering from heart failure induced by coro-
ary artery ligation [13]. Two recent studies indicated that puerarin
ay have the ability to reduce cardiac expression of transforming
rowth factor 1 (TGF1) in isoprenaline-treated mice or sponta-
eous hypertensive rats [14,15]. However, the effect of puerarin
n cardiac hypertrophy and the related signaling mechanisms still
eeds to be clariﬁed. In this study, we performed aortic banding
AB) to induce cardiac hypertrophy in mice and found out that
uerarin may  have an ability to retard the progression of cardiac
ypertrophy induced by pressure overload by targeting phospho-
nositide 3-kinase (PI3K)/Akt signaling and c-Jun N-terminal kinase
JNK) signaling pathways.
aterials  and methods
hemicals
Puerarin  (98% purity as determined by high-performance liquid
hromatography analysis) was purchased from Shanghai Winherb
edical S&T Development Co. Ltd. (Shanghai, China).
nimals
Male  C57/BL6 mice (23.5–27.5 g, 8–10 weeks old) used in this
tudy were purchased from the Institute of Laboratory Animal Sci-
nce, CAMS&PUMC (Beijing, China), and housed with controlled
emperature and humidity under a 12-h light–dark cycle with free
ccess to food and water in the Cardiovascular Research Institute
f Wuhan University (Wuhan, China). The animals were allowed
o acclimatize to the laboratory environment for at least one
eek, then randomly assigned to either a sham surgery or an
B group without or with puerarin treatment (diets containing
bout 65 mg/kg body weight/day) started one week after surgery
nd maintained for a further 7 weeks. The dose of puerarin was
esigned according to the literature [14]. The administration of
uerarin was performed according to previous studies [16,17].
ood consumption was monitored once a week and was  found to
e identical in all groups studied. The four groups were named
s sham + puerarin, AB + puerarin, sham + vehicle and AB + vehicle
espectively. AB was performed as described previously [18]. Eight
eeks after surgery, animals were subjected to ﬁnal echocar-
iography and catheter-based measurements of hemodynamic
arameters prior to sacriﬁce. All of the experiments were approved
y institutional guidelines of the Animal Care and Use Committee
f Renmin Hospital of Wuhan University and performed in accor-
ance with the Guide for the Care of Laboratory Animals published
y the US National Institutes of Health (NIH Publication No. 85-
3, revised 1996). All surgeries and analyses were performed in a
linded fashion for all groups.
chocardiography
Animals were subjected to echocardiographic analyses before
urgery as well as 1 and 8 weeks after surgery. Echocardiogra-
hy was performed in anesthetized (1.5% isoﬂurane) mice using
 Mylab 30CV (Esaote S.P.A, Genoa, Italy) equipped with a 10-MHz
inear array ultrasound transducer. The left ventricle (LV) dimen-
ions were assessed in parasternal short-axis view during systole or
iastole. LV end-systolic diameter (LVESD), LV end-diastolic diam-
ter (LVEDD), end-diastolic ventricular septal thickness (IVSd), and
eft ventricular posterior wall thickness (LVPWd) were measured
rom the LV M-mode tracing with a sweep speed of 50 mm/s  at the
id-papillary muscle level.iology 63 (2014) 73–81
Catheter-based measurements of hemodynamic parameters
For  hemodynamic measurements, mice were anesthetized with
1.5% isoﬂurane, and a microtip catheter transducer (SPR-839, Millar
Instruments, Houston, TX, USA) was  inserted into the left ventricle
via the right carotid artery. The signals were recorded using a Mil-
lar Pressure-Volume System (MPVS-400, Millar Instruments), and
the heart rate (HR), end-diastolic pressure (EDP), end-systolic pres-
sure (ESP), maximal rate of pressure development (dP/dt max), and
minimal rate of pressure decay (dP/dt min) were analyzed using the
PVAN data analysis software (Millar Instruments).
Histological analysis
Hearts  were removed, arrested in diastole with 10% KCl,
weighed, ﬁxed by perfusion with 10% formalin, and embedded in
parafﬁn. Hearts were cut transversely close to the apex to visu-
alize the left and right ventricles. Sections were cut of 4–5 m
and mounted onto slides. Hematoxylin and eosin (H&E) and
picrosirius red (PSR) staining were performed for histological anal-
ysis. Tissue sections were visualized by light microscopy. The
sections were stained for myocyte cross-sectional area with ﬂuo-
rescein isothiocyanate-labeled wheat germ agglutinin (Invitrogen,
Carlsbad, CA, USA) to visualize membranes and 4′,6-diamidino-
2-phenyl-indole (DAPI) to visualize nuclei. A single myocyte was
measured with a quantitative digital image analysis system (Image
Pro-Plus, version 6.0; Media Cybernetics, Bethesda, MD,  USA).
Between 100 and 200 myocytes in the left ventricles were outlined
in each group.
Quantitative real-time reverse transcription-polymerase chain
reaction
To  examine the relative mRNA expression of atrial natriuretic
peptide (ANP), B-type natriuretic peptide (BNP), -myosin heavy
polypeptide (-MHC), sarcoplasmatic reticulum calcium ATPase 2
alpha (SERCA2), connective tissue growth factor (CTGF), colla-
gen I, collagen III, ﬁbronectin, and TGF1, RNA  was collected from
LV tissue using TRIzol (Invitrogen, 15596-026), and reverse tran-
scribed into cDNA for real-time polymerase chain reaction (PCR)
analysis using oligo (DT) primers and the Transcriptor First Strand
cDNA Synthesis Kit (04896866001, Roche, Basel, Switzerland).
cDNA was synthesized from 2 g of total RNA. The PCR ampli-
ﬁcations were quantiﬁed using a LightCycler 480 SYBR Green 1
Master Mix  (Roche, 04707516001) and the results were normal-
ized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
gene expression.
Western blotting
Western blotting was  conducted to determine the activa-
tion state of PI3K/Akt signaling and mitogen-activated protein
kinase (MAPK) signaling. Protein amounts from all samples
were assessed using the BCA-kit (23227, Thermo Fisher Sci-
entiﬁc, Waltham, MA,  USA) followed by protein concentration
normalization prior to all Western blot experiments. Protein
samples (50 g) were separated by sodium dodecyl sulphate
polyacrylamide gel electrophoresis and then transferred to
immobilon-FL transfer membrane (IPFL00010, Millipore, Biller-
ica, MA,  USA). The membrane was  blocked with 5% milk in
Tris-buffered saline Tween-20 (TBST) for 3 h and then incu-
bated overnight at 4 ◦C with indicated primary antibodies.
Antibodies against the following proteins were purchased from
Cell Signaling Technology (Danvers, MA,  USA): phospho-PI3K
p85Tyr458/p55Tyr199 (#4228), PI3K p85 (#4257), phospho-AktSer473
(#4060), Akt (#4691), phospho-mammalian target of rapamycin
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mTOR)Ser2448 (#2971), mTOR (#2983), phospho-forkhead box O1
FoxO1)Ser256 (#9461), FoxO1 (#2880), phospho-FoxO3aSer318/321
#9465), FoxO3a (#2497), phospho-glycogen synthase kinase
 (GSK3)Ser9 (#9322), GSK3(#9315), phospho-extracellular
ignal-regulated kinase (ERK)1/2Thr202/Tyr204 (#4370), ERK1/2
#4695), phospho-p38Thr180/Tyr182 (#4511), p38 (#9212), phospho-
NK1/2Thr183/Tyr185 (#4668), JNK1/2 (#9285), Bax (#2772), Bcl-2
#2870). The antibody for GAPDH (MB001) was purchased from
ioworld Technology, St Paul, MN,  USA. The blots were scanned by
 two-color infrared imaging system (Odyssey, LI-COR, Lincoln, NE,
SA). Speciﬁc protein expression levels were normalized to GAPDH
rotein for total cell lysates.
ssessment  of apoptosis
Apoptosis  was assessed using terminal deoxynucleotidyl trans-
erase dUTP nick end labeling (TUNEL) staining according to the
rotocol of ApopTag® Plus Fluorescein In Situ Apoptosis Detec-
ion Kit (S7111, Chemicon, Temecula, CA, USA). Brieﬂy, 4 m thick
arafﬁn-embedded sections were prepared from mouse hearts of
ach group and deparafﬁnized sequentially. The sections were
tained with TUNEL reagents and -actinin, and the nuclei were
tained by DAPI. The numbers of apoptotic and total cells were
ounted, and the percentages of apoptotic cells were calculated.
ell  culture
The H9c2 cells (Cell Bank of the Chinese Academy of Sciences,
hanghai, China) were grown in high-glucose Dulbecco’s modiﬁed
agle’s medium (DMEM) (C11995, GIBCO, Grand Island, NY, USA)
upplemented with 10% (v/v) fetal bovine serum (GIBCO, 10099),
enicillin (100 U/ml) and streptomycin (100 mg/ml) (GIBCO,
5140) in humidiﬁed CO2 incubator (SANYO 18M, Osaka, Japan)
ith 5% CO2 at 37 ◦C. Cells at exponential growth were dissoci-
ted with 0.25% trypsin (GIBCO, 25200) and were seeded in six-well
ulture plates at a seeding density of 1 × 106/well before being incu-
ated for 24 h. Then cells were cultured with serum-free DMEM for
nother 12 h. Puerarin (82435, Sigma, St Louis, MO,  USA) was  dis-
olved in dimethyl sulfoxide (Sigma, D2650) at a concentration of
0 mmol/L. Ang II (Sigma, A9525) (1 M)  in the presence or absence
f different concentrations of puerarin (1 M,  5 M, 10 M,  20 M,
0 M)  were added to the medium and the cells were incubated for
4 h. Then total RNA was extracted from the H9c2 cells. The mRNA
xpression of ANP and BNP was examined by quantitative real-time
CR.
tatistical analysis
Data  were analyzed with a one-way ANOVA test followed by
 post hoc Tukey test. Values were expressed as the mean ± SEM.
chocardiographic data were analyzed using two-way ANOVA with
epeated measures and a post hoc Tukey’s test. p-Values of <0.05
ere considered signiﬁcant.
esults
uerarin  protected against cardiac hypertrophy
We determined whether puerarin administration started from 1
eek after AB surgery attenuated the indices of cardiac remodeling
nd heart failure. Mice subjected to AB surgery exhibited obvi-
us cardiac hypertrophy as evidenced by increased cardiac mass,
yocyte cross sectional area (CSA), heart weight/body weight
HW/BW), heart weight/tibial length (HW/TL), lung weight/body
eight (LW/BW), and lung weight/tibial length (LW/TL) at the endiology 63 (2014) 73–81 75
of 8 weeks compared to the sham group. However, 7 weeks of
puerarin administration attenuated these hypertrophic responses
(Fig. 1A and B). The induction of hypertrophic markers includ-
ing ANP, BNP, and -MHC after AB surgery was also signiﬁcantly
blunted in puerarin-treated mice; moreover, decreases in the
expression of -MHC and SERCA2 were normalized in puerarin-
treated mice (Fig. 1C).
Puerarin  improved the impaired cardiac function after AB
The  protective effect of puerarin against AB-induced left ven-
tricular dysfunction was  assessed by echocardiography before
surgery, 1 week after surgery but before starting puerarin treat-
ment, and ﬁnally 8 weeks after surgery. As shown in Fig. 2, animals
subjected to 1 week of AB suffered mild chamber diameter increase
and LV dysfunction, and the LVEDd, LVESd, EF, and fractional short-
ening (FS) were at the same level between the AB + vehicle group
and the AB + puerarin group. Eight weeks after AB, animals exhib-
ited signiﬁcantly increased chamber diameter and depressed EF
and FS, and puerarin administration resulted in attenuation of
cardiac dilation and improved LV function. Catheter-based hemo-
dynamic measurements were performed at the end of the study
to further assess LV systolic and diastolic function. Eight weeks
of AB resulted in signiﬁcantly increased diastolic blood pressure
and decreased systolic function and diastolic function, animals
treated with puerarin demonstrated normalization of these hemo-
dynamic parameters including EDP, dP/dt max, and dP/dt min
(Fig. 3). There were no signiﬁcant differences in HR between any
groups.
Puerarin attenuated pressure overload-induced cardiac ﬁbrosis
Fibrosis  is an integral feature of LV hypertrophy and heart
failure. We  performed PSR staining on cardiac tissue sections to
determine the development of interstitial ﬁbrosis in mice of each
group. Dramatic interstitial ﬁbrosis was  observed in mice subjected
to AB surgery, which was  attenuated by puerarin treatment (Fig. 4A
and B). We  also examined the changes in expression of myocardial
pro-ﬁbrotic genes at the end of the 8 weeks post surgery. As shown
in Fig. 4C, the pressure overload-induced expression of CTGF, col-
lagen I, collagen III, ﬁbronectin, and TGF1 was normalized by
puerarin.
Puerarin inhibited the activation of PI3K/Akt and JNK signaling
pathways after AB
To  investigate the molecular mechanisms by which puerarin
mediates its anti-hypertrophic effect, we examined the activation
state of PI3K/Akt and JNK signaling. Pressure overload increased the
phophorylations of PI3K, Akt, mTOR, GSK3, FoxO1, and FoxO3a
at 8 weeks after surgery. Interestingly, puerarin treatment signif-
icantly attenuated these increases as observed in Fig. 5A and B.
Similarly, upregulation of P-JNK1/2 was blunted by puerarin treat-
ment (Fig. 5C and D). However, puerarin did not affect the protein
levels of P-ERK1/2 and P-p38 (Fig. 5C and D).
Puerarin inhibits cardiomyocyte apoptosis in response to chronic
pressure  overload
Parafﬁn-embedded sections of hearts from each group were
co-stained for -actinin and TUNEL to determine the rate of car-
diomyocyte apoptosis. A noticeable increase in cardiomyocyte
apoptosis was observed in mice at 8 weeks after AB, and puerarin
treatment reduced AB-induced cardiomyocyte apoptosis (Fig. 6A).
76 Y. Yuan et al. / Journal of Cardiology 63 (2014) 73–81
Fig. 1. Puerarin protected against cardiac hypertrophy. (A) Gross hearts, hematoxylin and eosin staining and ﬂuorescein isothiocyanate-labeled wheat germ agglutinin
staining of sham and aortic banding (AB) mice at 8 weeks post surgery. (B) Statistical results of the heart weight/body weight (HW/BW) ratio, lung weight/body weight
(LW/BW) ratio, heart weight/tibial length (HW/TL) ratio, lung weight/tibial length (LW/TL) ratio, and myocyte cross-sectional areas (CSA) of indicated groups. (C) Expression
of  transcripts for atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), -myosin heavy polypeptide (MHC), -MHC, and sarcoplasmatic reticulum calcium ATPase
2  alpha (SERCA2) induced by AB were determined by reverse transcription-polymerase chain reaction analysis (n = 6). *p < 0.05 as compared with the corresponding sham
g
F
e
I
B
u
i
t
c
I
t
B
D
o
s
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urthermore, puerarin decreased the ratio of Bax/Bcl-2 protein
xpression in mice hearts after AB (Fig. 6B).
nhibitory effect of puerarin on the mRNA expression of ANP and
NP  in Ang II- (1 M) stimulated H9c2 cells
Treatment of H9c2 cardiomyocytes with Ang II (1 M,  24 h)
p-regulated the mRNA expression of the hypertrophic markers
ncluding ANP and BNP. The induction of ANP and BNP in response
o Ang II (1 M)  was restrained to different extents by different con-
entrations of puerarin (1 M,  5 M,  10 M,  20 M,  40 M)  (Fig. 7).
t indicated that treatment with puerarin led to a signiﬁcant reduc-
ion of the mRNA expression of the hypertrophic markers ANP and
NP in a concentration-dependent manner.
iscussionPrevious studies have provided support for the traditional uses
f kudzu root on cardiovascular, cerebrovascular, and endocrine
ystems including diabetes and its complications. Puerarin is a pure
xtract and the major bioactive constituent of kudzu root [7]. Inthis  study, we  found that 8 weeks after AB, mice developed car-
diac hypertrophy and ﬁbrosis characterized by increased HW/BW
ratio, HW/TL ratio, cross-section area of cardiomyocytes, collagen
accumulation, expression of hypertrophic and ﬁbrotic markers in
myocardium, leading to LV relative dilation and dysfunction. Car-
diomyocyte apoptosis and induction of Bax in response to AB were
suppressed by puerarin. Furthermore, the increased mRNA expres-
sion of ANP and BNP induced by Ang II (1 M)  was  restrained to
different extents by different concentrations of puerarin. Puerarin
treatment retarded the development of cardiac hypertrophy, ﬁbro-
sis, and apoptosis in mice subjected to pressure overload associated
with the regulation on PI3K/Akt and JNK pathways.
Much of the recent work has focused on the antipyretic [6],
anti-inﬂammatory [10], anti-oxidative [8], anti-apoptosis [12], and
estrogen-like biological activities of puerarin [19]. For more than
2000 years, kudzu root has been used as a herbal medicine for the
treatment of several diseases including fever, diabetes, and cardio-
vascular diseases [7]. As the major bioactive constituent in kudzu
root, puerarin injection has been widely used to treat coronary
heart disease and angina pectoris in clinical practice [20]. How-
ever, it is not clear whether puerarin can retard the process of
Y. Yuan et al. / Journal of Cardiology 63 (2014) 73–81 77
Fig. 2. Evidence of attenuation of aortic banding (AB)-induced left ventricular dysfunction by serial echocardiography. (A) Representative M-mode images of AB + vehicle and
AB  + puerarin groups. (B) Puerarin-attenuated AB-induced increased left ventricular (LV) diameters including LV end-systolic diameter (LVESd) and LV end-diastolic diameter
(LVEDd),  and also attenuated AB-induced changes in ejection fraction (EF) and fractional shortening (FS). Echocardiography was  performed before surgery (0 week), 1 week
after  surgery (1 week), and at the end of the study (8 weeks) (n = 9–10). Puerarin administration was started from 1 week after AB surgery. *p < 0.05 vs week 0, #p < 0.05 vs
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meek  1, p < 0.05 vs AB + vehicle group.
ardiac hypertrophy. Accordingly, our study addresses the poten-
ial of puerarin in protecting against cardiac hypertrophy in mice
ubjected to pressure overload.
Pressure  overload exerts a mechanical stress on the ventricles
nd can trigger not only cardiac hypertrophy but also ﬁbrosis [21].
ncreased cardiac collagen deposition is an important character of
brosis [22]. It was reported that puerarin could reverse chemical-
nduced liver ﬁbrosis in experimental rats [23]. In this study, we
ound that puerarin administration retarded the development of
brosis in pressure overloaded hearts. The mRNA expression of
rocollagen type I and III, the two major collagen types in the
eart, was reported to be increased in pressure overloaded heart
issue of mice [24]. It was also found that myocardial ﬁbrosis was
ediated through an interaction between the tumor necrosis factoralpha (TNF) and TGF pathways that led to increased expres-
sion of ﬁbrillar collagens [25]. Moreover, CTGF and ﬁbronectin are
pro-ﬁbrotic markers of ﬁbrosis [26,27]. As shown here, puerarin
could negatively regulate CTGF, collagen I, collagen III, ﬁbronectin,
and TGF1 production in response to pressure overload. Puerarin’s
ability to normalize expression of pro-ﬁbrotic genes reﬂects the
fact that puerarin may  also be effective in retarding extracellular
remodeling in post pressure overload myocardium although this
needs to be conﬁrmed by additional studies examining molecular
mechanisms of the ﬁbrotic process.We assessed the possible underlying mechanisms for puerarin
to retard cardiac hypertrophy and found that protein expression
of P-PI3K, P-Akt, P-GSK3, P-mTOR, P-FoxO1, P-FoxO3a, and P-
JNK increased signiﬁcantly in hearts of mice from AB + vehicle
78 Y. Yuan et al. / Journal of Cardiology 63 (2014) 73–81
Fig. 3. Normalization of hemodynamic parameters by puerarin. *p < 0.05 as compared with the corresponding sham group. #p < 0.05 vs AB + vehicle group. AB, aortic banding;
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aR,  heart rate; ESP, end-systolic pressure; EDP, end-diastolic pressure; dP/dt max, m
roup at 8 weeks after AB. Daily treatment with puerarin inhibited
he phosphorylations of PI3K, Akt, GSK3, mTOR, FoxO1, FoxO3a,
nd JNK induced by pressure overload. Our ﬁndings indicate that
uerarin’s ability to retard cardiac remodeling and heart fail-
re is likely mediated by the amelioration of the activation of
I3K/Akt and JNK signaling pathways. It was thought that life-
ong inhibition of PI3K might promote long-term heart beneﬁts
28], and PI3K/Akt and JNK signaling pathways have been thought
o be intimately related to cardiac hypertrophy and heart failure.
ig. 4. Puerarin-attenuated ﬁbrosis in pressure-overload hearts. (A) Histological sections
reas from histological sections were quantiﬁed using an image-analysis system. (C) The
II, ﬁbronectin, and transforming growth factor 1 (TGF1) in the myocardium were obta
nalysis. *p < 0.05 compared with the corresponding sham group. #p < 0.05 vs AB + vehicleal rate of pressure development; dP/dt min, minimal rate of pressure decay.
Studies  demonstrated that engagement of the p85 SH2  domains
of PI3K by pTyr relieved the p85-mediated inhibition of p110
isoforms, resulted in the activation of the PI3Ks p110, p110,
and probably also p110, and always led to the activation of Akt
[29]. It was also reported that the short-term activation of Akt
promoted physiological hypertrophy and protection from myocar-
dial injury, whereas, the long-term activation caused pathological
hypertrophy and heart failure [30]. GSK3, downstream of Akt,
is inactivated by phosphorylation of serine9 during hypertrophic
 of the left ventricle in indicated group were stained for picrosirius red. (B) Fibrotic
 mRNA expression of connective tissue growth factor (CTGF), collagen I, collagen
ined from indicated groups using reverse transcription-polymerase chain reaction
 group. AB, aortic banding.
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onditions [31], has been shown to be a negative regulator of
ardiomyocyte hypertrophy [32]. Another downstream target of
kt which is involved in cardiac hypertrophy is mTOR [33,34].
urthermore, cumulative Akt activation leads to inactivation of
orkhead transcription factors, which are negative regulators of car-
iac hypertrophy [35,36]. We  also found that MAPK signaling was
ctivated in pressure-overloaded hearts, which was  consistent with
revious studies [37,38]. Interestingly, puerarin blunted activation
f JNK without affecting ERK or p38 activity in vivo. As one of the
our best characterized MAPK subfamilies, JNK has been implicated
n promoting cardiac remodeling downstream of various pathways
39,40].
FoxO3a is a member of the forkhead family of transcription fac-
ors and an important substrate of Akt. One important function of
oxO3a is to induce apoptosis [41]. In our study, puerarin inhibited
ardiomyocyte apoptosis. Meanwhile, reduced phosphorylation of
oxO was identiﬁed in puerarin-treated hearts. It seemed confus-
ng. However, in contrast to the FoxO-inhibitory actions of Akt, JNK
s one of the kinases that are known to activate FoxO [42]. Chaanine
t al. investigated the relationship between JNK and Akt and they
ound that JNK signaling dominated and overrode Akt signaling,
ctivated FoxO3a in cardiac hypertrophy and heart failure, and
ig. 5. Effects of puerarin on the PI3 K/Akt and JNK signaling pathways. (A) Represent
apamycin (mTOR), P-glycogen synthase kinase 3 (GSK3), P-forkhead box O1 (FoxO
omparison of expression among the indicated groups. (C) and (D) Mitogen-activated p
lots of P-extracellular signal-regulated kinase (ERK)1/2, P-p38, P-c-Jun N-terminal kinase
esults. *p < 0.05 as compared with the corresponding sham group. #p < 0.05 vs AB + vehiciology 63 (2014) 73–81 79
further  promoted mitochondrial-induced apoptosis. It was consis-
tent with our ﬁndings [43].
Therefore,  inhibition of PI3K/Akt and JNK signaling by puerarin
may play a role in retarding the development of pressure overload-
induced alterations in cardiac structure and function in the aortic
banding mice model.
Our  results based on ﬁndings in in vivo studies suggest that
amelioration of PI3K/Akt and JNK-dependent processes represents
a viable mechanistic basis for the reversal of hypertrophy and rein-
force the concept that targeting the long-term activation of some
signaling pathways in cardiac hypertrophy and heart failure may
represent a key approach toward developing effective therapeutic
strategies although it is recognized that some signaling pathways
may be cardiac protective when short-term activated and other
potential intracellular targets for reversal of hypertrophy likely
exist. The in vitro studies indicate that treatment with puerarin led
to a signiﬁcant reduction of the mRNA expression of the hypertro-
phy marker genes ANP and BNP in Ang II (1 M)-stimulated H9c2
cells in a concentration-dependent manner. Further studies target-
ing the direct effect of puerarin on cardiac myocyte hypertrophy
may still be needed. We  did not evaluate the toxicology of puerarin
in this study, for it has a relatively low toxicity proﬁle [7].
ative blots of P-phosphoinositide 3-kinase (PI3K), P-Akt, P-mammalian target of
1), and P-FoxO3a in the heart tissues of mice in the indicated groups (n = 6). (B)
rotein kinase (MAPK) expression based on Western blot assay. (C) Representative
 (JNK)1/2 in the heart tissues of mice in the indicated groups (n = 6). (D) Quantitative
le group. AB, aortic banding; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Fig. 6. Puerarin inhibits cardiomyocyte apoptosis in response to chronic pressure overload. (A) Representative images and quantiﬁcation results of terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay in a section of mice hearts. (B) Cardia
as  compared with the corresponding sham group. #p < 0.05 vs AB + vehicle group. DAPI
phosphate dehydrogenase.
Fig. 7. Inhibitory effect of puerarin on the mRNA expression of atrial natriuretic
p
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of daidzein, a metabolite of puerarin and daidzin produced by human intestinal
microﬂora. Biol Pharm Bull 2002;25:1328–32.eptide  (ANP) and B-type natriuretic peptide (BNP) in Ang II (1 M) stimulated
9c2  cells. *p < 0.05 vs control group. #p < 0.05 vs Ang II group.
onclusion
Chronic oral treatment with puerarin retarded the progression
f cardiac hypertrophy and improved cardiac function in pres-
ure overloaded mice. This cardioprotective effect of puerarin was
elated to its inhibition of PI3K/Akt and JNK signaling. Puerarin may
ffer a potentially effective and relatively safe approach to retard
he processes of cardiac hypertrophy and heart failure particularly
n combination with other treatment modalities.onﬂict of interest
The  authors declare no conﬂict of interest.
[c expression of Bax and Bcl-2 determined by Western blotting analysis. *p < 0.05
, 4′ ,6-diamidino-2-phenyl-indole; AB, aortic banding; GAPDH, glyceraldehyde-3-
Acknowledgments
This  research was supported by the National Natural Science
Foundation of China (81000036 and 81000095) and the Fun-
damental Research Funds for the Central Universities of China
(2012302020212 and 2012302020211).
References
[1] Kutsuzawa D, Arimoto T, Watanabe T, Shishido T, Miyamoto T, Miyashita
T, Takahashi H, Niizeki T, Takeishi Y, Kubota I. Ongoing myocardial dam-
age in patients with heart failure and preserved ejection fraction. J Cardiol
2012;60:454–61.
[2]  Gjesdal O, Bluemke DA, Lima JA. Cardiac remodeling at the population level –
risk factors, screening, and outcomes. Nat Rev Cardiol 2011;8:673–85.
[3] Rouleau JL. New and emerging drugs and device therapies for chronic
heart failure in patients with systolic ventricular dysfunction. Can J Cardiol
2011;27:296–301.
[4] Hellawell JL, Margulies KB. Myocardial reverse remodeling. Cardiovasc Ther
2012;30:172–81.
[5]  Tamargo J, Lopez-Sendon J. Novel therapeutic targets for the treatment of heart
failure. Nat Rev Drug Discov 2011;10:536–55.
[6]  Yao XJ, Yin JA, Xia YF, Wei  ZF, Luo YB, Liu M,  Feleder C, Dai Y. Puerarin
exerts  antipyretic effect on lipopolysaccharide-induced fever in rats involv-
ing inhibition of pyrogen production from macrophages. J Ethnopharmacol
2012;141:322–30.
[7] Wong KH, Li GQ, Li KM,  Razmovski-Naumovski V, Chan K. Kudzu root: tra-
ditional uses and potential medicinal beneﬁts in diabetes and cardiovascular
diseases. J Ethnopharmacol 2011;134:584–607.
[8]  Liu CM, Ma  JQ, Sun YZ. Protective role of puerarin on lead-induced alterations
of the hepatic glutathione antioxidant system and hyperlipidemia in rats. Food
Chem Toxicol 2011;49:3119–27.
[9] Choo MK,  Park EK, Yoon HK, Kim DH. Antithrombotic and antiallergic activities10] Huang F, Liu K, Du H, Kou J, Liu B. Puerarin attenuates endothelial insulin
resistance through inhibition of inﬂammatory response in an IKKbeta/IRS-1-
dependent manner. Biochimie 2012;94:1143–50.
f Card
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[Y. Yuan et al. / Journal o
11] Zhang H, Zhang L, Zhang Q, Yang X, Yu J, Shun S, Wu Y, Zeng Q, Wang T. Puer-
arin: a novel antagonist to inward rectiﬁer potassium channel (IK1). Mol  Cell
Biochem 2011;352:117–23.
12] Liu CM,  Ma JQ, Sun YZ. Puerarin protects rat kidney from lead-induced apo-
ptosis by modulating the PI3K/Akt/eNOS pathway. Toxicol Appl Pharmacol
2012;258:330–42.
13]  He H, Shi M,  Yang J, Zeng X, Qiao H, Wu L, Li L. The correlation between
angiogenesis and abnormal expression of SERCA2a, phospholamban and the
endothelin pathway in heart failure, and improvement by puerarin. Phytother
Res 2008;22:948–56.
14]  Zhang NB, Huang ZG, Cui WD,  Ding BP. Effects of puerarin on expression
of cardiac Smad3 and Smad7 mRNA in spontaneously hypertensive rat. J
Ethnopharmacol 2011;138:737–40.
15] Chen R, Xue J, Xie M.  Puerarin prevents isoprenaline-induced myocardial ﬁbro-
sis in mice by reduction of myocardial TGF-beta1 expression. J Nutr Biochem
2012;23:1080–5.
16]  Tanaka T, Tang H, Yu F, Michihara S, Uzawa Y, Zaima N, Moriyama T, Kawamura
Y. Kudzu (Pueraria lobata) vine ethanol extracts improve ovariectomy-induced
bone  loss in female mice. J Agric Food Chem 2011;59:13230–7.
17] Shu C, Chen C, Zhang DP, Guo H, Zhou H, Zong J, Bian Z, Dong X, Dai J, Zhang Y,
Tang Q. Gastrodin protects against cardiac hypertrophy and ﬁbrosis. Mol  Cell
Biochem 2012;359:9–16.
18] Yan L, Wei  X, Tang QZ, Feng J, Zhang Y, Liu C, Bian ZY, Zhang LF, Chen M,  Bai
X, Wang AB, Fassett J, Chen Y, He YW,  Yang Q, et al. Cardiac-speciﬁc mindin
overexpression attenuates cardiac hypertrophy via blocking AKT/GSK3beta and
TGF-beta1-Smad signalling. Cardiovasc Res 2011;92:85–94.
19] Tang XL, Liu XJ, Tian Q, Zhang W.  Dynamic oxidative stress and DNA
damage induced by oestrogen deﬁciency and protective effects of puerarin
and 17 beta-oestradiol in ovariectomized rats. Basic Clin Pharmacol Toxicol
2012;111:87–91.
20]  Wang Q, Wu T, Chen X, Ni J, Duan X, Zheng J, Qiao J, Zhou L, Wei  J. Puerarin injec-
tion for unstable angina pectoris. Cochrane Database Syst Rev 2006:CD004196.
21] Fan D, Takawale A, Lee J, Kassiri Z. Cardiac ﬁbroblasts, ﬁbrosis and extracellular
matrix remodeling in heart disease. Fibrogenesis Tissue Repair 2012;5:15.
22] de Jong S, van Veen TA, de Bakker JM,  Vos MA,  van Rijen HV. Biomarkers of
myocardial ﬁbrosis. J Cardiovasc Pharmacol 2011;57:522–35.
23] Zhang S, Ji G, Liu J. Reversal of chemical-induced liver ﬁbrosis in Wistar rats by
puerarin. J Nutr Biochem 2006;17:485–91.
24] Zhou H, Bian ZY, Zong J, Deng W,  Yan L, Shen DF, Guo H, Dai J, Yuan Y,
Zhang R, Lin YF, Hu X, Li H, Tang QZ. Stem cell antigen 1 protects against car-
diac hypertrophy and ﬁbrosis after pressure overload. Hypertension 2012;60:
802–9.
25]  Kassiri Z, Defamie V, Hariri M,  Oudit GY, Anthwal S, Dawood F, Liu P, Khokha
R. Simultaneous transforming growth factor beta-tumor necrosis factor activa-
tion and cross-talk cause aberrant remodeling response and myocardial ﬁbrosis
in Timp3-deﬁcient heart. J Biol Chem 2009;284:29893–904.
26]  Koitabashi N, Arai M,  Kogure S, Niwano K, Watanabe A, Aoki Y, Maeno T, Nishida
T, Kubota S, Takigawa M,  Kurabayashi M.  Increased connective tissue growth
factor relative to brain natriuretic peptide as a determinant of myocardial ﬁbro-
sis. Hypertension 2007;49:1120–7.
27] Meems  LM,  Cannon MV,  Mahmud H, Voors AA, van Gilst WH,  Sillje HH, Ruifrok
WP,  de Boer RA. The vitamin D receptor activator paricalcitol prevents ﬁbrosis
[iology 63 (2014) 73–81 81
and diastolic dysfunction in a murine model of pressure overload. J Steroid
Biochem Mol  Biol 2012;132:282–9.
28] Shioi T, Inuzuka Y. Aging as a substrate of heart failure. J Cardiol 2012;60:423–8.
29] Vanhaesebroeck B, Guillermet-Guibert J, Graupera M,  Bilanges B. The emerg-
ing mechanisms of isoform-speciﬁc PI3K signalling. Nat Rev Mol  Cell Biol
2010;11:329–41.
30] Chaanine AH, Hajjar RJ. AKT signalling in the failing heart. Eur J Heart Fail
2011;13:825–9.
31]  Badorff C, Ruetten H, Mueller S, Stahmer M,  Gehring D, Jung F, Ihling C, Zeiher
AM, Dimmeler S. Fas receptor signaling inhibits glycogen synthase kinase 3
beta and induces cardiac hypertrophy following pressure overload. J Clin Invest
2002;109:373–81.
32]  Haq S, Choukroun G, Kang ZB, Ranu H, Matsui T, Rosenzweig A, Molkentin JD,
Alessandrini A, Woodgett J, Hajjar R, Michael A, Force T. Glycogen synthase
kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol
2000;151:117–30.
33]  Kurdi M,  Booz GW.  Three 4-letter words of hypertension-related cardiac hyper-
trophy: TRPC, mTOR, and HDAC. J Mol  Cell Cardiol 2011;50:964–71.
34] Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC,  Manning WJ,
Izumo S. Rapamycin attenuates load-induced cardiac hypertrophy in mice.
Circulation 2003;107:1664–70.
35] Skurk C, Izumiya Y, Maatz H, Razeghi P, Shiojima I, Sandri M,  Sato K, Zeng L,
Schiekofer S, Pimentel D, Lecker S, Taegtmeyer H, Goldberg AL, Walsh K. The
FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT
signaling. J Biol Chem 2005;280:20814–23.
36] Ronnebaum SM,  Patterson C. The FoxO family in cardiac function and dysfunc-
tion. Annu Rev Physiol 2010;72:81–94.
37] Cai WF,  Zhang XW,  Yan HM,  Ma  YG, Wang XX, Yan J, Xin BM,  Lv XX, Wang
QQ, Wang ZY, Yang HZ, Hu ZW.  Intracellular or extracellular heat shock pro-
tein 70 differentially regulates cardiac remodelling in pressure overload mice.
Cardiovasc Res 2010;88:140–9.
38] Esposito G, Prasad SV, Rapacciuolo A, Mao  L, Koch WJ,  Rockman HA. Cardiac
overexpression of a G(q) inhibitor blocks induction of extracellular signal-
regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure
overload. Circulation 2001;103:1453–8.
39] Choudhary R, Palm-Leis A, Scott 3rd RC, Guleria RS, Rachut E, Baker KM, Pan
J. All-trans retinoic acid prevents development of cardiac remodeling in aortic
banded rats by inhibiting the renin-angiotensin system. Am J Physiol Heart Circ
Physiol 2008;294:H633–44.
40] Fan GC, Yuan Q, Song G, Wang Y, Chen G, Qian J, Zhou X, Lee YJ, Ashraf M,
Kranias EG. Small heat-shock protein Hsp20 attenuates beta-agonist-mediated
cardiac remodeling through apoptosis signal-regulating kinase 1. Circ Res
2006;99:1233–42.
41]  Wu C, Jin B, Chen L, Zhuo D, Zhang Z, Gong K, Mao  Z. MiR-30d induces apoptosis
and is regulated by the Akt/FOXO pathway in renal cell carcinoma. Cell Signal
2013;25:1212–21.
42] Ferdous A, Battiprolu PK, Ni YG, Rothermel BA, Hill JA. FoxO, autophagy, and
cardiac remodeling. J Cardiovasc Transl Res 2010;3:355–64.
43] Chaanine AH, Jeong D, Liang L, Chemaly ER, Fish K, Gordon RE, Hajjar RJ.
JNK modulates FOXO3a for the expression of the mitochondrial death and
mitophagy marker BNIP3 in pathological hypertrophy and in heart failure. Cell
Death Dis 2012;3:265.
